1. Aceto Corp., based in New York, develops and sells human health products, pharmaceutical ingredients and performance chemicals. It filed for Chapter 11 bankruptcy Feb. 19. The decision was voluntary, made to facilitate the sale of its assets.
2. Immune Pharmaceuticals, a New Jersey-based biopharmaceutical company specializing in the development of treatments for immunologic and inflammatory diseases, filed for Chapter 11 bankruptcy Feb. 19. The drugmaker was unable to get funding to keep the company afloat, prompting its decision to file for bankruptcy protection.
3. Pernix Therapeutics, based in New Jersey, filed for Chapter 11 bankruptcy Feb. 18 amid lagging drug sales. The drugmaker also blamed its bankruptcy filing on increasing generic competition.
4. Imerys Talc America, which supplies talc for Johnson & Johnson’s baby powder, filed for Chapter 11 bankruptcy Feb. 13. In its bankruptcy filing, the Vermont company cited the more than 14,000 claims the company faces in U.S. courts that allege Imerys’ talc causes ovarian cancer or mesothelioma.
5. Novum Pharma, based in Chicago, filed for Chapter 11 bankruptcy Feb. 1. The drugmaker said that public backlash over its decision to raise the price of several dermatology products further increased prescription rejection rates and led to the bankruptcy filing.
More articles on pharmacy:
FTC settles with Teva over ‘pay-for-delay’ deals
Top 10 fatal or harmful prescribing errors
Civica Rx will start as middleman for drugmakers, hospitals, Bloomberg says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
